Fairness opinionsDigital / HealthTech2021

Inovalon Holdings acquired by Nordic Capital / Insight Partners: fairness opinion by Evercore and J.P. Morgan

Announced August 19, 2021 · Going-private · All cash · DEFM14A filed October 15, 2021
Digital / HealthTech Content / Consumer
Enterprise value
$7.3B
EV / LTM EBITDA
26.9x
EBITDA $271M · 35% margin
EV / LTM revenue
9.42x
revenue $775M
DCF discount rate
8.0%–9.0%
Perpetuity growth

Deal terms

ConsiderationAll cash
Price per share$41.00
Premium
Premium basisUnaffected closing price of $32.71 as of July 26, 2021 (last trading day prior to public report of rumored sale)
StructureGoing-private
Termination fee$176M (2.8% of equity)
Reverse termination fee$369M
Go-shopNone
Outside dateJanuary 16, 2022

Implied value per share by method vs. $41.00 offer

Selected companies — EV / 2021E Adjusted EBITDA (applied) (Evercore) $32.76 – $43.16
Selected companies — EV / 2022E Adjusted EBITDA (applied) (Evercore) $34.71 – $47.36
Selected companies — EV / 2021E Revenue (applied) (Evercore) $29.32 – $44.19
Selected companies — EV / 2022E Revenue (applied) (Evercore) $29.24 – $46.54
Precedent transactions — EV / LTM Revenue (applied) (Evercore) $26.81 – $45.20
Precedent transactions — EV / NTM Revenue (applied) (Evercore) $26.80 – $48.25
Discounted cash flow (Evercore) $33.83 – $51.31
Last 52-Week Trading Range (Evercore) $17.56 – $34.47
Equity Research Analyst Price Targets (Evercore) $23.00 – $45.00
Premiums Paid Analysis (Evercore) $39.25 – $44.16
Selected companies — FV / 2022E Adjusted EBITDA (J.P. Morgan) $34.00 – $45.75
Precedent transactions — FV / NTM Revenue (J.P. Morgan) $32.75 – $54.50
Discounted cash flow (J.P. Morgan) $34.00 – $51.75

Ranges as disclosed in the banker’s summary of analyses; the red line marks the per-share consideration.

Opinion of Evercore to the special committee

Delivered August 18, 2021

Discounted cash flow assumptions

Discount rate8.0%–9.0%
Basisestimate of the Company's weighted average cost of capital
Terminal valuePerpetuity growth
Perpetuity growth3.0%–4.0%
Exit multiple
Projection period2021E-2030E
Projections usedCompany management Projections and Extrapolations
Implied value per share$33.83–$51.31

Unlevered free cash flows discounted to present value as of August 3, 2021; net debt as of August 3, 2021 subtracted.

Selected public companies (18)

HealthEquity, Inc. · SignifyHealth, Inc. · Multiplan Corporation · Omnicell, Inc. · R1 RCM Inc. · Vocera Communications, Inc. · Tabula Rasa Healthcare, Inc. · Healthstream, Inc. · NICE Ltd. · PTC Inc. · Dropbox, Inc. · Cerence Inc. · Datto Holding Corp. · Qualys, Inc. · SPS Commerce, Inc. · Mimecast Limited · Cornerstone OnDemand, Inc. · Mitek Systems, Inc.

MultiplePeer lowPeer medianPeer highRange appliedImplied per share
EV / 2021E Adjusted EBITDA - Healthcare Payor Technology11.3x25.2x37.3x
EV / 2021E Adjusted EBITDA - Healthcare Provider Technology18.8x31.1x51.0x
EV / 2021E Adjusted EBITDA - Technology/Software14.8x27.5x39.0x
EV / 2021E Adjusted EBITDA (applied) 22.0x–28.0x $32.76–$43.16
EV / 2022E Adjusted EBITDA - Healthcare Payor Technology10.9x22.3x28.9x
EV / 2022E Adjusted EBITDA - Healthcare Provider Technology16.1x25.6x38.7x
EV / 2022E Adjusted EBITDA - Technology/Software12.6x23.7x32.5x
EV / 2022E Adjusted EBITDA (applied) 19.0x–25.0x $34.71–$47.36
EV / 2021E Revenue - Healthcare Payor Technology7.9x8.1x8.3x
EV / 2021E Revenue - Healthcare Provider Technology3.5x4.4x7.2x
EV / 2021E Revenue - Technology/Software5.4x8.8x12.8x
EV / 2021E Revenue (applied) 7.0x–10.0x $29.32–$44.19
EV / 2022E Revenue - Healthcare Payor Technology6.6x7.5x7.9x
EV / 2022E Revenue - Healthcare Provider Technology3.0x3.8x6.3x
EV / 2022E Revenue - Technology/Software5.0x7.8x10.9x
EV / 2022E Revenue (applied) 6.0x–9.0x $29.24–$46.54

Selected precedent transactions (17)

DateTargetAcquirerMultiple
2021-01Change Healthcare Inc.UnitedHealth Group Incorporated
2020-12HMS Holdings Corp.Gainwell Technologies
2019-06Medidata Solutions, Inc.Dassault Systemes SE
2018-11athenahealth, Inc.Veritas Capital
2018-06Cotiviti Holdings, Inc.Verscend Technologies, Inc.
2021-04Proofpoint, Inc.Thoma Bravo, L.P.
2021-04Nuance Communications, Inc.Microsoft Corporation
2021-04Blue Yonder, Inc.Panasonic Corporation
2020-12RealPage, Inc.Thoma Bravo, L.P.
2020-02Forescout Technologies, Inc.Advent International Corporation
2019-10Sophos Group plcThoma Bravo, LLC
2019-08Carbon Black, Inc.VMware, Inc.
2019-06Tableau Software, Inc.salesforce.com, inc.
2019-02The Ultimate Software Group, Inc.Hellman & Friedman LLC
2018-11Apptio, Inc.Vista Equity Partners
2018-10Red Hat, Inc.International Business Machines Corporation
2018-01Callidus Software Inc.SAP SE
MultipleLowMedianHighRange appliedImplied per share
EV / LTM Revenue - Healthcare Platform Technology4.3x5.1x8.8x
EV / LTM Revenue - Technology4.6x9.0x13.2x
EV / LTM Revenue (applied) 7.0x–11.0x $26.81–$45.20
EV / NTM Revenue - Healthcare Platform Technology4.1x4.4x7.6x
EV / NTM Revenue - Technology3.9x7.6x13.4x
EV / NTM Revenue (applied) 6.0x–10.0x $26.80–$48.25

Other analyses

AnalysisSummaryImplied per share
Last 52-Week Trading RangeLow and high closing prices during the twelve months ended July 26, 2021 (last trading day prior to public report of rumored sale).$17.56–$34.47
Equity Research Analyst Price TargetsRange of selected analyst price targets as of August 13, 2021.$23.00–$45.00
Premiums Paid Analysis21 selected transactions/announced bids for control of US public targets with transaction value between $1bn and $15bn in healthcare and technology since January 1, 2019; applied a 20%-35% premium range (25th-75th percentile) to the $32.71 unaffected closing price as of July 26, 2021.$39.25–$44.16

$3 million retainer fee payable on execution of engagement letter; $1 million opinion fee upon delivery of opinion, fully creditable against the $3 million retainer; plus an additional discretionary fee of up to $7 million at the Special Committee's sole discretion at conclusion of the assignment. Evercore received ~$9 million of fees from Nordic Capital X, ~$46 million from GIC and ~$57 million from Insight affiliates from Jan 1, 2019 to Aug 18, 2021.

Opinion of J.P. Morgan to the target board

Delivered August 19, 2021 · Fee $42.0M ($39.0M contingent on closing), $3.0M on delivery of the opinion

Discounted cash flow assumptions

Discount rate8.0%–9.0%
Basisweighted average cost of capital of the Company
Terminal valuePerpetuity growth
Perpetuity growth3.0%–4.0%
Exit multiple
Projection period2021E-2030E
Projections usedCompany management Projections and Extrapolations
Implied value per share$34.00–$51.75

Discounted to present value as of August 3, 2021; adjusted by subtracting net debt and other adjustments as of August 3, 2021.

Selected public companies (10)

NICE LTD. · PTC Inc. · Black Knight, Inc. · GoDaddy Inc. · Datto Holding Corp. · Qualys, Inc. · Mimecast Limited · Omnicell, Inc. · R1 RCM Inc. · Health Equity, Inc.

MultiplePeer lowPeer medianPeer highRange appliedImplied per share
FV / 2022E Adjusted EBITDA 18.5x–24.0x $34.00–$45.75

Selected precedent transactions (16)

DateTargetAcquirerMultiple
2021-04-23Blue Yonder Group, Inc.Panasonic Corporation
2021-04-12Nuance Communications, Inc.Microsoft Corporation
2019-08-22Carbon Black, Inc.VmWare, Inc.
2019-06-12Medidata Solutions, Inc.Dassault Systèmes
2019-06-10Tableau Software, Inc.Salesforce.com, Inc.
2018-10-28Red Hat, Inc.International business Machines Corporation
2018-06-19Cotiviti Holdings, Inc.Verscend Technologies, Inc.
2018-01-30Callidus Software Inc.SAP SE
2021-04-26Proofpoint, Inc.Thoma Bravo, L.P.
2020-12-21RealPage, Inc.Thoma Bravo, L.P.
2020-11-10Planview Inc.TA Associates
2020-02-06Forescout Technologies, Inc.Advent International
2019-10-14Sophos Group plcThoma Bravo, L.P.
2019-02-04Ultimate Software Group Inc.Hellman & Friedman LLC
2019-02-12Ellie Mae, Inc.Thoma Bravo, LLC
2018-11-11Apptio, Inc.Vista Equity Partners
MultipleLowMedianHighRange appliedImplied per share
FV / NTM Revenue 7.0x–11.0x $32.75–$54.50

Other analyses

AnalysisSummaryImplied per share
Reference pricesAnalyses compared to the unaffected closing price of $32.71 as of July 26, 2021, the closing price of $37.22 as of August 18, 2021, and the implied per share consideration of $41.00.

Estimated fee of $42 million, $3.0 million payable upon delivery of the opinion and the remainder contingent upon consummation of the Merger. J.P. Morgan recognized ~$15.2 million of aggregate fees from Nordic Capital X during the two years preceding the opinion; no fees from the Company or Parent.

3,000+ healthcare deal-level valuation multiples
The Valuation database includes financial details for more than 3,000 healthcare M&A transactions, private and public, with deal-level multiples, categorized by segment, type, and year.
See the Valuation database →

Management projections

Projection yearYear 1Year 2Year 3Year 4Year 5CAGR
Revenue$902M$1.0B$1.2B$1.4B$1.6B14.9%
Revenue growth16.4%15.3%15.4%15.4%13.6%
EBITDA$330M$404M$492M$594M$675M19.6%
EBITDA growth21.8%22.4%21.8%20.7%13.6%
EBITDA margin37%39%41%43%43%
Implied EV / EBITDA22.1x18.1x14.8x12.3x10.8x

Year-1 growth is against LTM at announcement ($775M revenue, $271M EBITDA); later years are year over year.

Company management prepared the "Projections and Extrapolations" covering fiscal 2021E-2025E (management forecast) and 2026E-2030E (management extrapolation), which the Special Committee directed Evercore and the Board directed J.P. Morgan to use. Revenue grows from $775 million in 2021E to $1,385 million in 2025E and $2,137 million in 2030E; Adjusted EBITDA grows from $271 million in 2021E to $594 million in 2025E and $917 million in 2030E. Unlevered free cash flow rises from $124 million in 2021E to $514 million in 2030E; EBIT from $153 million to $786 million.

Process notes

Going-private transaction with a related party (Rollover Stockholders including Meritas Group, Inc., which holds ~30% of the Company's capital stock; Dr. Dunleavy recused himself from Board deliberations). Two fairness opinions: Evercore for the Special Committee (Aug 18, 2021) and J.P. Morgan for the Company Board (oral Aug 18, 2021, written Aug 19, 2021). Schedule 13E-3 transaction; Audit Committee separately approved as a related-party transaction. No 'go shop' provision; Nordic Capital X refused one in exchange for a reduced Company Termination Fee (2.75% of equity value, down from proposed 3.5%). Outreach to over 30 potential bidders, 14 signed confidentiality agreements. Debt commitment up to $3.0 billion from Blackstone Credit, Owl Rock, Apollo entities; Limited Guarantee capped at $376,305,000.

Other Digital / HealthTech fairness opinions

All Digital / HealthTech opinions → · Evercore opinions · J.P. Morgan opinions